Guggenheim Maintains Buy on Tenet Healthcare, Lowers Price Target to $242
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Jason Cassorla maintains Tenet Healthcare (NYSE:THC) with a Buy and lowers the price target from $252 to $242.
Guggenheim analyst Jason Cassorla maintains Tenet Healthcare (NYSE:THC) with a Buy and lowers the price target from $252 to $242.